CRISPR Therapeutics

CRSP · NASDAQ🇨🇭

Overview

Earnings Dividends Seasonality Metrics

NOV

10

Q3 2025

Reported

Reported earnings 3 months ago

Previous year: -$1.01

+15.8%

R&D Expenses

$58.9M

Previous year: $82.2M

-28.3%

G&A Expenses

$16.9M

Previous year: $17.4M

-2.8%

Collaboration Expense

$57.1M

Previous year: $11.2M

Previous year: $2.26B

-0.5%

Loading...

CRISPR Therapeutics

Unlock previous datapoints

Upgrade

CRISPR Therapeutics

Unlock previous datapoints

Upgrade

CRISPR Therapeutics Revenue by Segment

Revenue by Segment

Grant Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$4.76B

P/E Ratio

-10.39

Sector

N/A

Industry

N/A

52-Week High

$76.6

52-Week Low

$31.2

R&D Expenses

$58.9M

G&A Expenses

$16.9M

Collaboration Expense

$57.1M

Marketable Securities

$1.63B

Working Capital

$1.81B

Products

Get in Touch

Resources

CRISPR Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics Revenue by Segment

Revenue by Segment

Grant Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics